High Velocity Hemodynamics Linked to Cerebral Microvascular VCAM-1 Expression in SCD
Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.
Why Sickle Cell Disease Clinicians Provide Different Contraceptive Guidance
New ASH 2021 data shows how guidance is still lacking for clinicians responsible for addressing contraception with women with sickle cell disease.
Novel Educational Programs Can Benefit and Engage Sickle Cell Patients
Children with sickle cell disease have the opportunity to learn about STEM concepts in the context of their own condition.
The Absolute Benefit of Daratumumab for Relapsed Refractory Multiple Myeloma
A continued conversation on the intricate, patient-centric benefits of care with the subcutaneous agent.
Elliott Vichinsky, MD: Voxelotor and New HOPE Data for Sickle Cell
The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.
Sickle Cell Neurocognitive Screening Measures May Have Inherent Educational Bias
New ASH data demonstrates that RUDAS and MoCA scores are associated with highest level of education.
Luspatercept for Beta-Thalassemia May Reduce Transfusion Burden, Maintain QoL
Luspatercept added to best supportive care reduced transfusion burden while TranQol and SF-36 HRQoL scores were maintained through Week 48.
New Lintuzumab Combination Therapy for AML Safe, Potentially Effective
A Phase I study reports on the safety and potential efficacy of lintuzumab Ac225 plus CLAG-M for relapsed/refractory acute myeloid leukemia.
Largest Hemophilia B Gene Therapy Study to Date Hits Early Benefit, Safety Marks
The historic phase 3 HOPE-B trial shows all but 1 treated patient discontinued prophylaxis after a single dose of etranacogene deaparvovec.
New Gene Therapy Product ARU-1801 Shows Durable, Safe Sickle Cell Effect
The second process of ARU-1801 in a new patient resulted in up to 4 times greater engraftment of transduced hematopoietic stem cells and progenitors at 6 months.
Daratumumab Plus Pomalidomide Significantly Benefits Relapsed/Refractory Multiple Myeloma
An interview with a Janssen expert on the growing portfolio and newest data for daratumumab.
Cerebral Arteriopathy Risk More Common in Sickle Cell Anemic Children
The sickle cell disease subtype is associated with increased risk among patients as young as 2 years old.
New PKR Activator for Sickle Cell Shows Promising Safety, Efficacy Results
In data presented at ASH 2020, FT-4204 shows early potential in being safe, efficacious treatment for sickle cell disease.
Mitapivat Demonstrates Safety, Tolerability Among Sickle Cell Disease Patients
The ongoing phase I study also demonstrates that the drug is associated with an increase in Hb from baseline with a concomitant decrease in hemolytic markers.
Early Initiation of Rivipansel for VOC in Sickle Cell Disease
Early initiation reduces hospital stays and length of IV opioid use.
Exercise-Induced Vital Sign Changes May Predict Sickle Cell Prognosis
Analyses of vital sign changes from the 6-minute walk test may be indicative of cardiopulmonary function and potential survival among patients with sickle cell disease.
Anticoagulant, Antiplatelet Use Not Linked to Better COVID-19 Outcomes
The new findings show worsened outcomes among particular comorbid patient groups, as well as minority patients.
Jeffrey Wolf, MD: Optimizing Multiple Myeloma Assessment
A discussion on what the future of monitoring the rare disease may entail, and how COVID-19 interrupted in-person assessment earlier this year.
Venetoclax-Obinutuzumab Significantly Improves Chronic Lymphocytic Leukemia Survival
The combination therapy was linked to a record phase 3 progression-free survival rate among a subpopulation of patients with the rare cancer.
Measurable Residual Disease Could Improve Multiple Myeloma Treatment Decisions
A discussion with a study author and longtime expert on improving monitoring of the rare disease.
Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients
The furthest-progressed gene-edited therapy for a genetic disease reported historic efficacy data in ongoing phase 1/2 trials.
mHealth App Improves Sickle Cell Disease Symptoms
The app improved pain, fatigue, and quality of life in children with the disease.
Cognitive, Emotional Measures Linked to Sickle Cell Healthcare Utilization
A study finds that children with cognitive or emotional deficits trended towards an increased healthcare utilization.
LentiGlobin for Sickle Cell Has Potential to Improve Health-Related Quality of Life
Patients with baseline PROMIS-57 scores worse than population norms reported clinically significant improvements in 6 of 8 domains at 12 months post-treatment.
High COVID-19 False-Negative Rate Among Patients With Hematological Malignancies
Faster initiation of COVID-19 treatment is associated with better outcomes in patients with hematological malignancies.
COVID-19 and Hematological Diseases Linked to High Mortality Rate
Patients with acute myeloid leukemia or myelodysplastic syndromes are at especially increased risk for increased disease severity and death.
Vaccine Could Provide Long-Term Acute Myeloid Leukemia Remission
New data from an ongoing trial showed patients achieved MRD negative status after a vaccine regimen—and have maintained status over a year.
Study Reports on Thrombotic Rates Among COVID-19 Patients
Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.
Targeted Gene Editing May Provide a Sickle Cell Disease Cure
Early assessment from an Australian team of investigators is targeting a pathway linked to hemoglobin expression.
Novel Genetic Loci May Be Linked with HbF Expression in Sickle Cell Children
High levels of fetal hemoglobin have previously been linked to the mitigation of morbidity and mortality of sickle cell anemia.